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ABSTRACT
Clinical treatment for osteoarthritis (OA) is very impor-
tant and is based on patient’s self care and guided by the 
physician. Drug therapy is additional to losing weight, 
improving muscular strength, proprioception, flexibility 
and range of motion. Between the available drugs for 
osteoarthritis’ treatment, some are basically analgesics 
and do not interfere on disease’s progression; some are 
anti-inflammatory with good analgesic power but with 
side effects that compromise their prolonged usage; and 
the structure modifying drugs that slow down the pro-
gression of OA. The medications are presented in topic, 
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INTRODUCTION
Until a few decades ago, the treatment of os-
teoarthritis or osteoarthrosis (OA) was limited to 
the use of simple analgesics, anti-inflammatory 
drugs, physical measures (weight loss, muscle 
strengthening, and physical therapy modalities), 
infiltration with corticosteroids and, in refrac-
tory and more serious cases, surgical treatment. 
The progressing understanding of the pathophy-
siology of osteoarthritis in the knee, the percep-
tion that the process is not purely mechanical and/
or an aging process, and the elucidation of the 
inflammatory pathways involved led to the cli-
nical application of many other medications. 
Although a cure for osteoarthritis is still beyond the 
reach of medicine, there has been discussion regarding 
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oral, intra-muscular, intra-venous and intra-articular
forms. The hyaluronic acid has various presentations 
with good analgesic effect and some evidence of struc-
ture modifying property. There is IA evidence level for 
the use of diacerhein and of glucosamine to slow down 
the disease. Still, more technology for diagnosis and 
therapy control of OA is necessary to define the efficacy 
of other drugs.
Keywords – Osteoarthritis; Anthraquinone; Glucosamine; 
Condroitin; Hyaluronic acid
the existence of disease-modifying drugs, which have 
the ability to alter the course of joint degeneration, 
slow its progression, and possibly make it asympto-
matic, thereby avoiding a portion of protective surgical 
procedures.
Since researchers expect that if medication can 
slow the disease, it can also render it asymptomatic, 
most of the studies with structure-modifying drugs are 
of short duration and compare them with fast-acting 
analgesic drugs. OA is a disease of slow evolution. 
Radiographic changes take three years to be observed/
measured. The very loss of knee joint space is more 
related to the extrusion of the meniscus than the loss 
of femoral-tibial cartilage.
Over the years, researchers have learned that pain 
in OA can be controlled without intervening in the 
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HYALURONIC ACID
Synovial fluid in OA shows reduced viscoelastici-
ty(2,3). For the lubrication and protection of cells and 
joint tissues, high viscoelasticity is essential. Thus, 
one of the causes of pain and decreased joint mobility 
may be the decrease in the protective effect of this 
viscoelastic medium through the pain receptors in the 
synovial tissue(4). Viscosupplementation is a relatively 
new therapy that acts directly on the causes of pain 
and stiffness in OA, replacing the synovial medium 
with low viscoelasticity with a highly viscoelastic 
hyaluronic acid solution(5-7).
There are various preparations of hyaluronic acid 
on the market and their different rheological pro-
perties are primarily dependent on their molecular 
weights(8). With a molecular weight of 6x106 dal-
tons (Da), the viscoelastic properties of hylan GF 
20 are similar to the synovial fluid of healthy young 
adults(3); three weekly injections have been proven to 
be safe and superior in efficacy compared to placebo 
(infiltration of saline solution or arthrocentesis)(9,10) 
with analgesia up to six months. With a molecular 
weight of 500-730kDa, the viscoelastic properties of 
sodium hyaluronate (Na-HA) are smaller than those 
of normal synovial fluid, but proved to be viscosi-
ty inducers (i.e., inducing the synovium to produce 
hyaluronic acid of higher molecular weight)(11). The 
results of these preparations with lower molecular 
weight compared with injection of saline or arthro-
centesis vary, sometimes revealing a statistical diffe-
rence, sometimes revealing no difference(12-14).
Studies comparing the high molecular weight pre-
paration (hylan GF 20) with other low weight prepara-
tions have been published in recent years, with varying 
results. Some showed no statistical difference(15), while 
others showed greater efficacy in the compound with 
high molecular weight(16-18), and others still showed a 
greater efficacy in the compound with low molecular 
weight(11,19,20). Another study showed a similarity be-
tween treatment with hyaluronic acid and treatment 
with only physical measures/physical therapy(18). 
A recent meta-analysis(21) showed that the use of 
hyaluronic acid has little effect compared to intra-
-articular placebo and that compounds with high mo-
lecular weight tend to have better results (faster and 
prolonged analgesia in OA).
Hyaluronic acid may have a structure-modifying 
effect. A randomized study(22), in which patients un-
derwent knee arthroscopy at the beginning and end of 
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disease process. The opposite also occurs. You can 
intervene in the process of OA without resolving all of 
the pain. The pain is multifactorial and is also related 
to the degree of OA.
Markers of OA (in blood and urine) are being re-
searched, particularly to assess if the arthritis is pro-
gressing or is under control.
In this update, we will discuss primarily the medi-
cations that are considered structure-modifiers in the 
disease and what level of evidence supports their use.
PATHOPHYSIOLOGY OF OA
Although OA is a disease of the entire joint (cartila-
ge, ligaments, synovium, and bone), the initial lesion is 
usually in the articular cartilage. OA has a strong genetic 
component and, in most cases, has mechanical overload 
as an initiator of the process of cartilage damage, which 
evolves to a vicious inflammatory cycle, perpetuating 
joint degradation. This inflammatory pathway has as 
its primary agents interleukin-1 (IL-1) and tumor ne-
crosis factor (TNF), which induce increased expression 
of metalloproteinases and nitric oxide (NO), the main 
catabolic agents produced by chondrocytes in response 
to injury, in addition to more IL-1. Treatment of osteo-
arthritis can target both the mechanical overload that 
leads to joint damage and the inflammatory cycle that 
perpetuates the injury at one or more points in this chain.
To facilitate the study of the medication options 
used in osteoarthritis, it is customary to divide drugs 
into two main groups: fast-acting symptomatic drugs 
and slow-acting drugs. Among the latter are the struc-
ture-modifying drugs (which also include fast-acting 
analgesic drugs and those of prolonged action), which 
are discussed below. It should be remembered that 
drug therapy has to be seen as a complement, and 
not a replacement, for non-drug therapy. The primary 
objective of conservative treatment of OA is self-care 
(weight loss and motor control)(1).
SPECIFIC DRUGS FOR THE 
TREATMENT OF OA
Within this group are the medications that act more 
specifically in the disease process of osteoarthritis, 
having in theory the ability to be disease-modifying 
(preventing, slowing, reversing, or stabilizing the alte-
ration of joint structure). There is evidence to suggest 
that some of these drugs are structure modifiers.
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one year of treatment with four series of three weekly 
injections of hyaluronic acid (6-8 x 105), showed less 
deterioration of the cartilage and more organelle syn-
thesis in cartilage treated with hyaluronic acid than in 
the cartilage of those injected with saline. A prospecti-
ve, randomized, blind study(23) showed no radiological 
difference between the placebo and the medication 
in one year, although the time was too short to eva-
luate radiological differences in a method for treating 
osteoarthritis. However, it was noted that separating 
only the group of patients with the largest joint spa-
ce (less severe osteoarthritis, where there are more 
chondrocytes to be influenced or not by the drug), 
hyaluronic acid showed significantly better results. 
Possible complications are infection (risk similar to 
the injection of corticosteroids) and local inflamma-
tory reaction that occurs in up to 3% of cases, with 
symptoms lasting up to three weeks.
Thus, there is evidence of the good and prolonged 
analgesic effect of hyaluronic acid, and that the hi-
gher the molecular weight, the greater its analgesic 
power. What molecular weight would best preserve 
the articular cartilage is not known with certainty. 
Some animal studies tend to suggest that a molecu-
lar weight between 0.6 and 1.0 x 106Da would best 
stimulate the production of the matrix components, 
which may be partially explained by the fact that the 
lower molecular weight would more easily penetrate 
the extracellular matrix, maximizing concentration, 
and also facilitating its interaction with target cells 
of the synovium. In addition, there is evidence that 
the binding of hyaluronic acid molecules with cell 
receptors is dependent on the molecular weight(11). 
Studies show that high molecular weight HA also 
stimulates synthesis organelles(24). This observation 
of which molecular weight better protects articular 
cartilage in animals has not been tested in humans(11). 
There are preparations that are taken from the crest of 
the rooster; patients allergic to bird products should 
not be injected with such preparations. There is hya-
luronic acid produced by fermentation, which has a 
lower molecular weight, albeit without the problems of 
allergens or cross-links between molecules of hyaluro-
nic acid that can lead to synovitis during the process 
of breaking these cross-links.
Hyaluronic acid should not be injected into knees 
with synovitis. The synovitis should be first treated 
or punctured, and can be injected with the first vial of 
hyaluronic acid into 1 ml of triamcinolone(25).
DIACEREIN
It acts mainly by inhibiting the effects of IL-1 that 
degrades the protein inhibitor of nuclear factor kappa-
-beta, which leads to transcription of nitric oxide,
IL-1, TGF, and metalloproteinases(26-29), and also has ana-
bolic properties, stimulating the production of  TGF-B 
and proteoglycans, collagen, and hyaluronic acid(30).
Besides its effectiveness in relieving symptoms of 
osteoarthritis, its disease-modifying action by its 
smaller decrease of joint space relative to place-
bo has been proven in a long-term (three years), 
multicenter, prospective study. That is, level of 
evidence IA that it is a disease-modifying osteoar-
thritic drug, delaying the development of OA(31). 
The recommended dosage is 100 mg/day(32), attention 
should be given to the possible side effect of altering 
intestinal peristalsis. It can be administered to patients 
with renal or cardiac insufficiency(31,32).
GLUCOSAMINE
Glucosamine participates in the synthesis of glyco-
saminoglycans (GAGs), proteoglycans, and hyaluro-
nate in articular cartilage, although the exact mecha-
nism has not yet been elucidated(33). In addition to 
functioning as a substrate, it acts directly on chon-
drocytes, stimulating the synthesis of proteoglycans 
and inhibiting the synthesis of metalloproteinases. It 
inhibits the effects of IL-1 on nuclear factor kappa-
-beta in the chondrocyte layer, also inhibiting the pro-
duction of nitric oxide, more IL-1 and TGF. It acts on 
osteoclasts and the synovium(34).
Recent meta-analysis showed that the drug has 
superior efficacy to placebo, and that, in addition to 
symptomatic improvement, it decreases the effect of 
joint narrowing(33-36). There are three types of glu-
cosamine in the market. Glucosamine hydrochlori-
de (HCl – removed from crab shells), glucosamine 
sulfate (taken from the shells of deep-water shrimp), 
and synthetic glucosamine (sulfate). There is level 
of evidence IA that synthetic glucosamine slows 
the development of OA (continuous use for three
years)(37) and this effect is maintained even five 
years after cessation of drug use(38). Its dosage is 
simple. The dose is 1500 mg daily. In the case of 
synthetic glucosamine, this dose leads to a concen-
 !" #$%&$'&()*+$,& #%&  -.&/,$$0&"%0&12%$3#",& ',4#0&
(minimum therapeutic dose of glucosamine). Glu-
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cosamine hydrochloride, given at a dose of 500 mg 
 -!..& #5.1&"&0"26&!."7-.1&"&7$%7.% !" #$%&$'&8*+$,&#%&
the synovial fluid (less than the therapeutic dose)(39,40).
CHONDROITIN
Chondroitin sulfate is a GAG found in various 
human tissues, including hyaline cartilage. Studies 
show, in addition to direct stimulation of cartilage, its 
inhibiting action on IL-1 and metalloproteinases(41,42). 
Chondroitin is a large molecule, which is broken 
when absorbed by the intestine. There is glucosami-
ne in its formation.
Recent meta-analysis showed that the drug has 
efficacy superior to placebo, with symptom relief as 
its predominant effect, without reducing the joint nar-
rowing of glucosamine(33,35,36,43).
The recommended dose is 1200 mg/day.
COMBINATION OF GLUCOSAMINE 
AND CHONDROITIN
The combination of drugs, acting in different 
ways with complementary effects, would be better 
than isolated use. The usual dosage is 1500 mg of 
glucosamine and 1200 mg of chondroitin in single 
or divided daily dose, depending on the commercial 
composition. It shows good tolerance to prolonged 
use with few side effects.
The GAIT study (Glucosamine HCl/chondroitin 
Arthritis Intervention Trial), multicenter, double-blind, 
randomized, with placebo- and celecoxib-(selective 
NSAID COX-2 inhibitor) controlled groups, was re-
cently published(44). The study included 1583 patients, 
and results after 24 weeks showed that in the general 
group the combination of drugs, from the standpoint 
of analgesia, was not superior to placebo, whereas 
celecoxib was. Separating only patients with mode-
rate to severe pain, there was statistical difference 
compared to placebo, suggesting greater benefit in 
this patient group.
AVOCADO AND SOYBEAN 
UNSAPONIFIABLES
They are proven inhibitors of IL-1, IL-6, IL-8, and 
metalloproteinases in vitro(45) and chondrocyte stimu-
lators in vitro(46).
A review article of four randomized, double-blind, 
placebo-controlled studies showed improvement of 
symptoms in three; however, the only long-term study 
among these showed negative results for hip osteoar-
thritis, but positive results for knee OA(47). A recent 
meta-analysis (2008) of controlled studies with soy-
bean and avocado unsaponifiables showed that their 
use reduces pain, reduces the intake of analgesics, and 
improves function in patients with knee OA(48). Ne-
vertheless, the ability of this drug to prevent joint spa-
ce loss in osteoarthritis is not yet clear. A prospective 
randomized study evaluating the hip joint space after 
using the medication showed significant results only in 
the subgroup with advanced osteoarthritis, without sig-
nificant results in the study population as a whole(49).
With a dose of 300 mg/day, the Brazilian consen-
sus on OA (OARSI) indicates the use of soybean and 
avocado unsaponifiables for the treatment of OA.
CHLOROQUINE
It shows a suppressive effect in the NO production 
induced by IL-1(50).
Its clinical efficacy in the treatment of osteoar-
thritis has not been established; however, it seems to 
be particularly useful in inflammatory and erosive 
forms of osteoarthritis. In Brazil, there is a consensus 
statement (OARSI) for chloroquine as a treatment 
option for OA.
OTHER DRUGS
Many other substances of natural and synthetic ori-
gin have been studied for their supposed antiarthritic 
effects. Even gene therapy has been investigated for 
application in the treatment of osteoarthritis.
We should continue to expect much in the future 
of the clinical treatment of osteoarthritis.
FINAL CONSIDERATIONS 
As we have seen, there are several medications 
available with the potential to modify the progression 
of osteoarthritis by acting directly on the pathophysio-
logy of the disease. Nevertheless, based on scientific 
evidence, one can conclude that:
- Hyaluronic acid improves pain and function for pa-
tients with osteoarthritis;
- Diacerein and synthetic glucosamine slow the pro-
gression of osteoarthritis.
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